Australia news live: productivity commissioner warns of job cuts coming from AI; aged care provider to close
Update:
Date: 2025-06-11T20:32:16.000Z
Title: Welcome
Content: Good morning and welcome to our live news blog. I'm Martin Farrer with the top overnight stories and then it will be Nick Visser to take you through the day.
The new industry and science minister, Tim Ayres, warns today that Australia must 'lean in hard' to the benefits of artificial intelligence or else risk ending up 'on the end of somebody else's supply chain'. His comments follow an appearance by Australia's productivity commissioner on 7.30 last night in which she said AI could cost jobs. More coming up.
We'll bring you news soon of a big aged care provider which is closing next month.
And parties in Tasmania will be gearing up for another election campaign today after the state's governor said she had been left with no choice but to call a poll to resolve the Apple Isle's political crisis. We'll have the latest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
24 minutes ago
- Daily Mail
Waleed Aly issues dark warning about the future of Australian TV after the death of The Project in powerful essay he 'never wanted to write'
Waleed Aly has warned free-to-air television is 'staring into the abyss' after The Project, which he co-hosted for 14 of its 16 years, was suddenly axed. In a column for The Age newspaper - that Aly insisted he never really wanted to write - the public intellectual and TV personality warned the Network Ten show's demise was a consequence of the growing power of the tech giants. 'As a general rule, I don't commentate on my own work. My editors urged me to reconsider, then left me to it,' he wrote. 'Improbably, then, here we are. But only because there are bigger things at stake than the fate of this or that television show.' Aly noted that free-to-air TV was losing audience to streaming services but highlighted a bigger threat: that tech giants, such as Meta and Google, were collecting 'frankly unconscionable amounts of their users' personal data'. Therefore, they could target audiences with better tailored ads than TV ever could. 'That will remain so for as long as television doesn't turn the camera on you and monitor your every move,' Aly wrote. 'What has inevitably followed is a flight, not so much of audiences, but of advertisers to these tech giants. 'This, I think, is a major problem. Not because free-to-air television is uniquely precious, but because that amount of data collection in the hands of a select few tech moguls simply shouldn't be allowed to exist.' The Project co-host said the tech giants has been allowed to grow 'with no serious regulation' and governments were doing nothing to stop them. Then he took aim at artificial intelligence and how it could follow the same path as the likes of Facebook and Google - with users' intimate data used to create an 'advertising product'. Aly noted that ChatGPT's parent company OpenAI was considering incorporating advertising. Aly ended his piece warning of the 'empires' that were being built in television's place 'and precisely what will have been plundered to erect them'. Network Ten announced it will be replacing the Project with a news program, known as 10 News+, from 6pm. The news program will be hosted by Denham Hitchcock and Amelia Brace - both formerly of the Seven Network - and is being helmed by executive producer Daniel Sutton, a veteran Ten reporter. In an interview with Mediaweek, Mr Sutton said the new show would go deeper than the typical 6pm news fare of 'car crashes, house fires and state politics.' 'We'll go in depth on issues that affect Aussies, and get into the "why", not just the who, what and when. 'And when we break a big story, we'll have the time to explain it and dig into the detail.' 10 News+ will start Monday, June 30, on 10 and 10 Play.
The Guardian
2 hours ago
- The Guardian
News live: Albanese heads to Fiji talks en route to G7; authorities ‘urgently following up' whether any Australians affected by Air India crash
Update: Date: 2025-06-12T21:23:52.000Z Title: Welcome Content: Good morning, Nick Visser here to guide you through today's breaking news. Here's what's on the cards this morning: Prime minister Anthony Albanese will leave Canberra this morning en route to the G7 meeting in Canada early next week. The trip will include stops in Fiji and the US, will all eyes on a potential sideline meeting with Donald Trump, although nothing has been confirmed. The Department of Foreign Affairs expressed condolences to those affected by the Air India crash in the city of Ahmedabad last night. The Australian high commission and consulate-general are 'urgently following up' with local authorities to determine if any Australians were impacted. Defence minister Richard Marles again downplayed the US review of the Aukus submarine deal, telling the ABC last night he believes it is 'completely appropriate' for the Trump administration to look into it. Stick with us.
Reuters
2 hours ago
- Reuters
US FDA puts on hold Rein Therapeutics' lung disease drug trial
June 12 (Reuters) - Rein Therapeutics (RNTX.O), opens new tab has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after the Food and Drug Administration placed a clinical hold, the drug developer said on Thursday. Shares of the company fell nearly 10% after the bell. The company was testing a drug named LTI-03 to treat patients with idiopathic pulmonary fibrosis (IPF). The disease causes scarring of the lungs that makes it harder for them to work properly. Rein said in a filing that it is actively working with the FDA to remove the clinical hold. The FDA and Rein did not immediately respond to Reuters' requests for comment on why the hold was placed. The drug was well-tolerated and safe in an early-stage study in patients with IPF, the company said in the filing. No drug-related serious adverse events have been reported in any studies treating patients with LTI-03, it added. Rein continues to study the drug and enroll patients in Australia and Europe.
